Archive | M&A RSS feed for this section

3 Reasons Why this Biotech Rally is the Real Deal

After dropping some 20% in 2016, the biotech sector could be set for the rally of a lifetime in 2017 and make current investors a fortune in the process. See why Bret Jensen thinks this rally is for real in today’s article.  The biotech sector was one of the poorest performers in the market in […]

Read more

3 Stocks That are Ripe for a Takeover

By investing in these three mid-cap stocks with emerging growth stories you can greatly increase your chance of owning a stock that gets taken out by a larger player. Especially since their sector is flush with big companies holding loads of cash and looking to buy growth. Biotech had its best weekly performance in more […]

Read more

4 Takeover Targets in the Market’s Hottest Sector

There has been a fast and furious resurgence in M&A in this sector with tens of billions of dollars of deals going down in just the last couple of months. With expectations that dealmaking will continue to increase, consider these four stocks as solid investments with the chance for huge returns if they are purchased […]

Read more

The Next 3 Major Biotech Takeover Targets

After record years for deal volume in both 2014 and 2015 in the biotech and pharma industries, M&A transactions have posted a significant decline in the volume of deals so far in 2016 across these industries. As of late August, transactions based on dollar volume were down almost 65% from the same period in 2015. […]

Read more

4 Likely Biotech Takeover Targets to Buy

After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist. It was a good week for the Biotech Gems portfolio. Progenics Pharmaceuticals (NASDAQ: PGNX) leapt 25% in […]

Read more

3 Undervalued Stocks with Strong Upcoming Catalysts

If all goes well for these three stocks, in the next six months they could be worth over double the prices they currently trade for. Each stock has important, business-defining events that, if positive (and it’s likely they will be), would make their businesses significantly more valuable. I get dozens of questions every week on […]

Read more

Top 3 Buyout Targets in Tech

Microsoft may have started a feeding frenzy for tech buyouts in the social media space. This could be the catalyst we’ve been waiting for to finally see some big name buyouts. Here are the top three to watch for this summer. Microsoft (NASDAQ: MSFT) has inked the sixth largest tech deal ever, agreeing to pay […]

Read more

5 Biotech Takeover Targets Ripe for Acquisition

Don’t let the resurgence in M&A in the biotech sector pass you by. Big pharma companies have set their sights on small and mid-cap stocks and have shelled out offers with big premiums. Bret Jensen shares his top five picks for likely acquisition targets in biotech. We are starting to see some of the “animal […]

Read more

6 Strong Buys to Outperform This Summer

The best stocks to buy this summer will be ones that derive almost all of their revenues here in the United States. These six stocks won’t have their profits squeezed by a strengthening dollar and are growing their businesses when many areas of the market remain stagnant.  Memorial Day weekend has come and gone. This […]

Read more

2 Undervalued Stocks with Safe and Growing Dividends

Lock in historically high dividend yields from these two safe and undervalued stocks now while they are still cheap. Market volatility may be here to stay, but these two stocks can shield your portfolio while also returning above average income. I just got back from the Money Show conference in Las Vegas where I delivered […]

Read more